Alkermes reports positive Phase 1b topline results for ALKS 7290 in adult ADHD
Alkermes said it has positive topline results from a Phase 1 proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor (OX2R) agonist, in adults with attention-deficit hyperactivity disorder (ADHD).
Alkermes plc (Nasdaq: ALKS) said it reported positive topline results from a phase 1 proof-of-concept study of ALKS 7290, its novel investigational orexin 2 receptor (OX2R) agonist being developed for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated ALKS 7290 in adults with ADHD.